Detailed explanation of common side effects of Nintedanib and how to deal with them

Nintedanib is a multi-target tyrosine kinase inhibitor mainly used to treat diseases such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related pulmonary fibrosis and non-small cell lung cancer (NSCLC). As an anti-fibrotic and anti-tumor drug, nintedanib can inhibit multiple signaling pathways, delay disease progression, and improve patient survival. However, during clinical application, patients often experience varying degrees of side effects. If these adverse reactions are not effectively managed, they may affect the continuity and efficacy of treatment. The following will introduce in detail the common side effects of nintedanib and the corresponding treatment methods to help patients and medical staff improve the safety of medication.
1. Gastrointestinal reactions
Gastrointestinal side effects are the most common adverse reactions of nintedanib, especially diarrhea, nausea, vomiting and abdominal pain. According to clinical data, more than 40% of patients will suffer from diarrhea, and some patients even have moderate to severe diarrhea, which affects their daily life.
Countermeasures:
For mild diarrhea, you can adjust your diet, such as avoiding greasy and spicy foods, and increasing water replenishment, which can help relieve symptoms.
Appropriate use of antidiarrheal drugs (such as loperamide) can effectively control symptoms, but they should be used under the guidance of a doctor to avoid long-term dependence.
For nausea and vomiting, try small meals more frequently before taking medication, avoid eating on an empty stomach, and use anti-nausea medications if necessary.
If the gastrointestinal reaction is severe and affects appetite and nutrient absorption, the dose of nintedanib should be adjusted or even temporarily discontinued, and the medication can be gradually resumed after the symptoms are relieved.
2. Abnormal liver function
Nintedanib can cause increases in liver function indicators, including increases in transaminases (ALT, AST) and total bilirubin. This is especially noticeable in some patients during the initial period of medication or during dose adjustment.
Countermeasures:
Liver function should be monitored regularly before the start of treatment and during medication, especially 1 month before medication and once a month in the initial stage of treatment. Subsequent monitoring frequency should be adjusted according to the situation.
Patients with mild liver function abnormalities generally do not need to discontinue medication, but should be closely observed and maintained for regular review.
If severe liver function damage occurs (transaminase exceeds the normal upper limit by more than 5 times), the medication should be suspended and liver protection treatment should be carried out. After the liver function returns to a safe range, the dose can be reduced and restarted as appropriate.

Patients with abnormal liver function should avoid drinking alcohol and using other hepatotoxic drugs at the same time to reduce the burden on the liver.

3. Skin and mucous membrane reactions
Some patients may experience skin and mucosal adverse reactions such as rash, itching, stomatitis or mucosal ulcers. Although most cases are mild, they have a certain impact on quality of life.
Countermeasures:
Keep your skin clean and moisturized and avoid using harsh skin care products.
Oral mucosal problems can be relieved by gargling with salt water or medical oral care products.
For rashes and itching, your doctor may recommend topical low-dose corticosteroid creams or antihistamines to relieve symptoms.
People with severe skin reactions should seek medical treatment promptly and adjust or suspend medications if necessary.
4. Bleeding risk
As a multi-target kinase inhibitor, nintedanib may increase the risk of bleeding in patients, especially those who are combined with anticoagulant therapy or have bleeding tendencies.
Countermeasures:
The patient's bleeding risk should be assessed before use, and combination with strong anticoagulants should be avoided.
If symptoms such as subcutaneous bleeding, nose bleeding, and gum bleeding occur, you should report it to your doctor in time.
When bleeding is severe, medication needs to be suspended and symptomatic treatment must be actively carried out.
Monitor coagulation indicators regularly and adjust relevant treatments if necessary.
5. Other adverse reactions
In addition, patients may experience less common side effects such as fatigue, headache, weight loss, and high blood pressure. Some patients may also be at increased risk of lung infection and should take precautions.
Countermeasures:
Based on the patient's specific symptoms, symptomatic treatment and lifestyle intervention are adopted, such as moderate rest, nutritional support, and blood pressure control.
Pay close attention to symptoms of infection and seek medical treatment promptly.
Nintedanib plays an important role in delaying the progression of pulmonary fibrosis and treating lung cancer, but the related side effects cannot be ignored. Patients and medical staff should pay attention to the early identification and management of side effects, establish a complete follow-up mechanism, and adjust treatment plans in a timely manner to ensure that patients obtain maximum treatment benefits while reducing the impact of adverse reactions on life. Reasonable side effect management not only improves patient compliance, but also promotes the continued effectiveness of treatment, which is the key to achieving long-term disease control.
Reference: https://www.drugs.com/